Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5586882 | Cytokine | 2017 | 6 Pages |
Abstract
Interleukin-35 (IL-35) is a recently discovered inhibitory cytokine, which is firstly discovered to be produced by regulatory T cells (Tregs) and proposed as a key effector molecule of Treg function. This study aims to analyze the correlation between IL-35 expression in tumor-infiltrating lymphocytes (TILs) of breast cancer tissue and patients' clinical characteristics. Plasma IL-35 was also determined in 60 patients with breast invasive ductal carcinoma (IDC) and 30 healthy women by enzyme-linked immunosorbent assay. IL-35 expression in the tissue specimens was analyzed by immunohistochemistry. It was shown that 39.1%, 43.6% and 17.3% of the 110 patients were absent, weak, and strong IL-35 expression in the TILs, respectively. Strong IL-35 expression in TILs was significantly associated with age >50Â years, tumor size >2Â cm, TNM stage III, and negative ER (All PÂ <Â 0.05). Patients with elevated IL-35 expression in TILs had significantly worse progression-free survival (PFS) and overall survival (OS) than patients with weak or no IL-35 expression (All PÂ <Â 0.05). High plasma IL-35 levels were significantly associated with TNM stage III and lymph node metastasis (All PÂ <Â 0.05). Plasma IL-35 level and IL-35 expression in the TILs of breast cancer tissues may be a valuable biomarker in the development and prognosis of IDC.
Keywords
EGFRhuman epithelial growth factor receptor 2IL-35EBI3HER2IDCTregsPFsInterleukin-35Bregsprogression-free survivaloverall survivalTumor-infiltrating lymphocytesTILSNSCLCNon-small cell lung cancerBreast cancerregulatory B cellsRegulatory T cellsInvasive ductal carcinomaEstrogen receptorEpidermal growth factor receptorProgesterone receptor
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Zhonghua Zhao, Xi Chen, Shengnan Hao, Rui Jia, Nana Wang, Shaoshui Chen, Mianli Li, Chuanxin Wang, Haiting Mao,